Wall Street pushed higher on Friday and closed at record highs across all three major averages. For the week, the Nasdaq Composite climbed 2.4%, the S&P 500 moved up 1.4%, and the Dow added 0.9%. The S&P 500 Health Care Index Sector ( XLV ) gained 0.1% during the week. The top S&P 500 healthcare gainers and losers for the last week are as follows: Top Gainers: Agilent Technologies ( A ) +18.07% Ch...
Wall Street pushed higher on Friday and closed at record highs across all three major averages. For the week, the Nasdaq Composite climbed 2.4%, the S&P 500 moved up 1.4%, and the Dow added 0.9%. The S&P 500 Health Care Index Sector ( XLV ) gained 0.1% during the week. The top S&P 500 healthcare gainers and losers for the last week are as follows: Top Gainers: Agilent Technologies ( A ) +18.07% Charles River Laboratories International ( CRL ) +13.75% Waters ( WAT ) +12.49% Veeva Systems ( VEEV ) +10.15% Revvity ( RVTY ) +9.61% Top Losers: Boston Scientific ( BSX ) -15.47% Universal Health Services ( UHS ) -10.06% ResMed ( RMD ) -8.81% Insulet ( PODD ) -7.62% Medtronic ( MDT ) -5.55% Here are some of the important healthcare stories from this week: Pfizer signs up to $10.5B oncology deal with China’s Innovent Pfizer ( PFE ) and Innovent Biologics ( IVBIY ) ( IVBXF ) entered into a global oncology partnership worth up to $10.5B , underscoring growing demand among multinational drugmakers for innovative therapies developed by Chinese biotech companies. Hong Kong-listed shares of Innovent Biologics surged over +11% on Friday following the announcement. The deal covers a portfolio of 12 oncology programs, comprising eight Innovent-originated early-stage assets and four Pfizer-proposed discovery programs. The companies will co-develop and share costs for select programs as they advance these programs through clinical development. Under the financial terms of the agreement, Innovent will receive a $650M upfront payment and is eligible for up to $9.85B in development, regulatory, and commercial milestone payments. Additionally, Innovent will receive up to double-digit royalties on sales of each licensed product if approved. For the ‘co-developed, co-commercialized’ programs, the two companies will share the profits in the U.S. and Europe. The transaction is expected to close in the third quarter, subject to fulfillment of required regulatory approvals. UnitedHealth sued by ...
Amazon (NASDAQ: AMZN) was a surprise stock pick when Berkshire Hathaway picked up shares in 2019. As a tech stock, it's not the classic Buffett stock, but the major consumer element and dominant position fit right in. Warren Buffett attributed the purchase to one of the investing managers, but he also said he should have bought it earlier. The stock gained 131% from the end of the third quarter of...
Amazon (NASDAQ: AMZN) was a surprise stock pick when Berkshire Hathaway picked up shares in 2019. As a tech stock, it's not the classic Buffett stock, but the major consumer element and dominant position fit right in. Warren Buffett attributed the purchase to one of the investing managers, but he also said he should have bought it earlier. The stock gained 131% from the end of the third quarter of 2019, when it was purchased, through the end of the first quarter of 2026, when it was sold. Continue reading
A university student in Hong Kong who recently received a letter from Chinese President Xi Jinping has said that an ocean voyage, a food delivery app and having a curious mind have helped break stereotypes and bridge gaps between Chinese and American youths. Liu Runjie, a fourth-year electronic engineering student at the Chinese University of Hong Kong (CUHK), was among 20 young people who joined ...
A university student in Hong Kong who recently received a letter from Chinese President Xi Jinping has said that an ocean voyage, a food delivery app and having a curious mind have helped break stereotypes and bridge gaps between Chinese and American youths. Liu Runjie, a fourth-year electronic engineering student at the Chinese University of Hong Kong (CUHK), was among 20 young people who joined a China-US youth friendship programme and shared their experiences with Xi, prompting a reply from...
The comedian on coming out at 20, discovering she was funny, and the special moment she marked with a tattoo Born in Portsmouth in 1986, comedian Suzi Ruffell trained at the Academy of Live and Recorded Arts in London and began her standup career in 2008. As well as touring and appearing on Live at the Apollo, she hosts a podcast, Out With Suzi Ruffell, and co-hosts another, Like Minded Friends, w...
The comedian on coming out at 20, discovering she was funny, and the special moment she marked with a tattoo Born in Portsmouth in 1986, comedian Suzi Ruffell trained at the Academy of Live and Recorded Arts in London and began her standup career in 2008. As well as touring and appearing on Live at the Apollo, she hosts a podcast, Out With Suzi Ruffell, and co-hosts another, Like Minded Friends, with Tom Allen. She has also written a bestselling memoir, Am I Having Fun Now? Anxiety, Applause and Life’s Big Questions, Answered. She tours her show The Juggle until September. This was taken in the living room of the house I grew up in, in Portsmouth. All the curtains were heavily patterned, as were the carpets. I was 10 years old and deep in my Spice Girls era – especially Mel C, who was on the roster of my early crushes, along with Kate Winslet and Jennifer Aniston. Continue reading...
A new belief set is uniting some of the wealthiest men in the world around a ‘transhuman’ future – actual humanity be damned Sam Altman, the chief executive of OpenAI, took to the Internet a few years ago to propose that homo sapiens would be the first species “to design our own descendants”. In his best case scenario, the “merge” between humans and artificial intelligence occurs at some point ove...
A new belief set is uniting some of the wealthiest men in the world around a ‘transhuman’ future – actual humanity be damned Sam Altman, the chief executive of OpenAI, took to the Internet a few years ago to propose that homo sapiens would be the first species “to design our own descendants”. In his best case scenario, the “merge” between humans and artificial intelligence occurs at some point over the next 50 years. The alternative, where we remain simply human and the machines follow their own path, is more ominous. “If two different species both want the same thing and only one can have it – in this case, to be the dominant species on the planet and beyond – they are going to have conflict,” he wrote. More recently, Elon Musk, the world’s richest man, who at one point last year was granted the power to reconfigure the US federal government, argued on his social media platform, X, that “it increasingly appears that humanity is a biological bootloader for digital superintelligence” – our role in the history of the cosmos reduced to that of the low level code that boots up a computer before you can run sophisticated programs on it. Continue reading...
Serious health conditions are being misdiagnosed and pregnancies are missed while the internet swells with terrible advice and meno-products. Enough! Ladies! Are you tired all the time, sweaty and hot, or headachy? Do you have a range of the vague complaints (laziness, hysteria, dissolute habits, general languishing) that would have seen you committed to a 19th-century asylum ? Are you lacking in ...
Serious health conditions are being misdiagnosed and pregnancies are missed while the internet swells with terrible advice and meno-products. Enough! Ladies! Are you tired all the time, sweaty and hot, or headachy? Do you have a range of the vague complaints (laziness, hysteria, dissolute habits, general languishing) that would have seen you committed to a 19th-century asylum ? Are you lacking in joie de vivre? Maybe you’re perimenopausal! Or maybe you’re not: being tired, hot and over everything are also symptoms of simply being alive in spring 2026 . That’s not what the internet wants you to believe, though: last week, experts issued a warning about the deluge of perimenopause and menopause misinformation online and the risks that can pose to women, including unwanted pregnancies and a failure to seek a diagnosis for serious health conditions. Continue reading...
Scottish family on low income receives £15,000 more a year than identical household in England The emergence of “welfare nationalism” in the UK has created striking differences in benefit entitlement that result in a Scottish family on a low income receiving £15,000 a year more in state support than an identical household over the border in England. A typical out of work couple with four children ...
Scottish family on low income receives £15,000 more a year than identical household in England The emergence of “welfare nationalism” in the UK has created striking differences in benefit entitlement that result in a Scottish family on a low income receiving £15,000 a year more in state support than an identical household over the border in England. A typical out of work couple with four children would have received £22,000 a year benefit income in York, compared with £32,000 in Belfast and £37,000 in Glasgow, according to new research on the impact of devolved welfare approaches Continue reading...
The long-running series in which readers answer other readers’ questions on subjects ranging from trivial flights of fancy to profound scientific and philosophical concepts If an alien landed and asked you: “What is this thing you call music?” what would you play for them? And why? Heather, Kent Post your answers (and new questions) below or send them to nq@theguardian.com . A selection will be pu...
The long-running series in which readers answer other readers’ questions on subjects ranging from trivial flights of fancy to profound scientific and philosophical concepts If an alien landed and asked you: “What is this thing you call music?” what would you play for them? And why? Heather, Kent Post your answers (and new questions) below or send them to nq@theguardian.com . A selection will be published next Sunday. Due to a production error, a new Notes & Queries question was not published on 24 May. Continue reading...
A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better treatments for one of the deadliest types of cancer. (Image credit: Min Yu/AP)
A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better treatments for one of the deadliest types of cancer. (Image credit: Min Yu/AP)
Chipmakers are by far the hottest stocks in the market, but their recent surge is lending urgency to the debate over whether investors are buying into an artificial-intelligence bubble that’s due to burst. The Philadelphia Stock Exchange Semiconductor Index is on pace for its best quarter ever after soaring 69% in the past two months. Chips are the best performing sector in the S&P 500 Index this ...
Chipmakers are by far the hottest stocks in the market, but their recent surge is lending urgency to the debate over whether investors are buying into an artificial-intelligence bubble that’s due to burst. The Philadelphia Stock Exchange Semiconductor Index is on pace for its best quarter ever after soaring 69% in the past two months. Chips are the best performing sector in the S&P 500 Index this year by a wide margin. The gains have gotten so extreme and widespread that the group is now heavily represented among the benchmark’s leading stocks. The most dramatic moves are coming from the memory side of the business, where overwhelming demand for high-bandwidth chips used in AI data centers is sending prices skyrocketing. Micron Technology Inc. ’s shares have more than tripled this year. In Asia, SK Hynix Inc. has soared 260%, and Samsung Electronics Co. , the world’s biggest maker of memory chips, is up 165%. All three now have market capitalizations above $1 trillion , meaning taken together they’re suddenly worth more than the Magnificent Seven’s Meta Platforms Inc. and Tesla Inc. combined. This is where the debate comes in. Bulls see a boom driven by structural changes that are transforming the notoriously cyclical semiconductor industry. Bears see an overheated market fascinated by the latest shiny object. And investors are caught in the middle, transfixed by the momentum, but wary of what could come next. “You could see another leg up if you’re looking to buy here, but I keep going back to how volatile chips can be, and how everything can be great until it’s not,” said Ed O’Gorman , chief executive and managing partner at River Wealth Advisors, which holds positions in semiconductor giants Nvidia Corp. and Broadcom Inc. The stakes are high because the stock market has become so reliant on chipmakers for growth. Almost 80% of the S&P 500’s 11% gain this year is coming from just 10 companies — all are in technology and seven are semiconductor stocks. The two bigg...
(Bloomberg) -- Chipmakers are by far the hottest stocks in the market, but their recent surge is lending urgency to the debate over whether investors are buying into an artificial-intelligence bubble that’s due to burst.Most Read from BloombergUS Says Deals With Iran for Safe Hormuz Transit Are ProhibitedAmericans Injured in Iranian Missile Strike on Kuwaiti Air BaseStrait of Hormuz Ship Transits ...
(Bloomberg) -- Chipmakers are by far the hottest stocks in the market, but their recent surge is lending urgency to the debate over whether investors are buying into an artificial-intelligence bubble that’s due to burst.Most Read from BloombergUS Says Deals With Iran for Safe Hormuz Transit Are ProhibitedAmericans Injured in Iranian Missile Strike on Kuwaiti Air BaseStrait of Hormuz Ship Transits Are Rising Thanks to US HelpAmericans Hurt in Kuwait as Trump Sends Mixed Signals on WarCVS Returns
The Enhanced Games — a singular sporting competition where a majority of the athletes were on performance enhancing drugs — may herald a new business model that the tech industry is ready to embrace.
The Enhanced Games — a singular sporting competition where a majority of the athletes were on performance enhancing drugs — may herald a new business model that the tech industry is ready to embrace.
The crypto weed vape found me on 4/20, the high holiday of cannabis enthusiasts everywhere. It arrived over Slack with the thumbnail of a man exhaling a plume of vapor, the words "every hit delivers Bitcoin" emblazoned across it. It claimed to be advertising a device called Gudtrip, and I thought everything about it sounded fake. So I went looking for it. What I eventually found, after weeks of se...
The crypto weed vape found me on 4/20, the high holiday of cannabis enthusiasts everywhere. It arrived over Slack with the thumbnail of a man exhaling a plume of vapor, the words "every hit delivers Bitcoin" emblazoned across it. It claimed to be advertising a device called Gudtrip, and I thought everything about it sounded fake. So I went looking for it. What I eventually found, after weeks of searching, dozens of emails, and a reporting effort that spanned continents, was somehow even dumber than I'd imagined. My first port of call was Gudtrip's website , which only made the vape seem more like a prank. The company's description of the pr … Read the full story at The Verge.
tupungato/iStock Editorial via Getty Images In late April, after Microsoft’s ( MSFT ) shares had only started to rebound after a massive depreciation in value that lasted a few months, I stated that the selloff made little sense. I still think so to this day. While Microsoft’s stock has appreciated by ~7% since that article came out, there are reasons to believe that the stock has much more room f...
tupungato/iStock Editorial via Getty Images In late April, after Microsoft’s ( MSFT ) shares had only started to rebound after a massive depreciation in value that lasted a few months, I stated that the selloff made little sense. I still think so to this day. While Microsoft’s stock has appreciated by ~7% since that article came out, there are reasons to believe that the stock has much more room for growth and the rebound is just getting started. First of all, the new agreement between OpenAI ( OPENAI ) and Microsoft, which was signed a month ago, has created new opportunities for the latter to better benefit from its stake in the creator of ChatGPT. A separate deal with Anthropic ( ANTHRO ) that was signed at the end of 2025 already has the potential to create $43 billion in additional revenue annually by 2030 for Microsoft. More importantly, as Microsoft accelerates the deployment of AI data centers, it can experience an additional boost in cloud revenues in the near future. All of this indicates that Microsoft has plenty of growth opportunities, and its upside seems to be significant. This is why it looks like a no-brainer move to own Microsoft right now, especially at the current beaten-down price. There’s Nothing Not To Like About Microsoft One of the most significant things that has happened since the release of my latest articles on Microsoft is the company’s reworked deal with OpenAI. Under the new agreement, OpenAI revenue-sharing payments to Microsoft will be capped at $38 billion through 2030. While this is a good thing for OpenAI, the new agreement has also created new growth opportunities for Microsoft. Going forward, Microsoft would no longer be required to share revenues from Azure sales of OpenAI models to its clients. On top of that, OpenAI has also lost the option to defer some of the payments that it owes to Microsoft. As a result, Microsoft is expected to collect ~$6 billion this year instead of the previously expected $4 billion. But that’s not ...
Colombians are voting in presidential elections in which the economic model, counter-narcotics policies and relations with Washington are all at stake. Senator Iván Cepeda , an ally of leftist President Gustavo Petro , has pledged to tax the rich, boost social spending, seek peace deals with cocaine-trafficking militias. His main opponents, Abelardo de la Espriella and Paloma Valencia, in contrast...
Colombians are voting in presidential elections in which the economic model, counter-narcotics policies and relations with Washington are all at stake. Senator Iván Cepeda , an ally of leftist President Gustavo Petro , has pledged to tax the rich, boost social spending, seek peace deals with cocaine-trafficking militias. His main opponents, Abelardo de la Espriella and Paloma Valencia, in contrast, both say they’ll curb spending, cut taxes and fight rather than negotiate with criminal groups. And while Cepeda has been critical of US interventions in Latin America, and opposes fracking, his rivals want to seek more US military aid to fight cocaine-trafficking groups, and legalize unconventional oil and gas extraction. But whereas Valencia is a senator from the conservative establishment, De la Espriella is a celebrity defense attorney with a gift for social media, who created his own political group. One of the two is likely to face Cepeda in a June 21 runoff. Petro is barred by the constitution from seeking a second term. Colombia’s stocks, bonds and currency are likely to rally on a strong performance by De la Espriella or Valencia, or sell off if Cepeda beats expectations. That’s because investors fear that a Cepeda administration would undermine central bank independence and run up debt. “Markets will be scrutinizing the margin by which Iván Cepeda, the probable first-round winner, outpaces his nearest rivals,” said Mario Carvajal, a consultant at Colombia Risk Analysis. The next president, who’ll take office Aug. 7, will inherit a fiscal deficit that widened to nearly 7% of gross domestic product last year, as well as a security crisis fueled by record cocaine production. S&P Global Ratings downgraded Colombia ’s sovereign credit rating to BB-, its lowest-ever level, after Petro’s government last year suspended the fiscal rule, which limited the government’s ability to run up debt. Extortion, kidnappings and terrorist attacks surging over the past four years, as...
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that ivonescimab, the Company's first-in-class PD-1/VEGF bispecific antibody, has achieved a statistically significant and clinically meaningful improvement in overall survival (OS) as a first-line treatment for patients with advanced squamous non-small cell lung cancer (sq-NSCLC) in the Phase III HARMONi-6 (AK112-306) study. These l...
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that ivonescimab, the Company's first-in-class PD-1/VEGF bispecific antibody, has achieved a statistically significant and clinically meaningful improvement in overall survival (OS) as a first-line treatment for patients with advanced squamous non-small cell lung cancer (sq-NSCLC) in the Phase III HARMONi-6 (AK112-306) study. These landmark findings will be featured in a Plenary Session at the 2026 American Society of Clinical Onco
SlavkoSereda/iStock via Getty Images The 1-Minute Market Report May 31, 2026 I tip my hat to the fearless dip-buyers, who have a historic winning streak of nine consecutive up weeks. There are only four streaks since 1950 that were longer. What does this mean? Do these long streaks foretell above-average returns going forward? I’m afraid not. Streaks of five or more weeks are followed by average r...
SlavkoSereda/iStock via Getty Images The 1-Minute Market Report May 31, 2026 I tip my hat to the fearless dip-buyers, who have a historic winning streak of nine consecutive up weeks. There are only four streaks since 1950 that were longer. What does this mean? Do these long streaks foretell above-average returns going forward? I’m afraid not. Streaks of five or more weeks are followed by average returns over the following 12 months. There was plenty of action in other aspects of the market, and we will cover it all in the charts and tables below, beginning with a snapshot of the past four weeks. S&P 500 Last Four Weeks Here is a look at the last four weeks of the 9-week rally. It was a 4-day week and all four days were record highs. The direction is clearly higher. S&P 500 last 4 weeks (ZenInvestor) Zoom out to twelve months When we look at the market on a month-by-month basis, we can see how powerful this rally has been since the end of March. April was up 10.4%, and May has finished with a very respectable gain of 5.1%. S&P 500 monthly returns (ZenInvestor) S&P 500 drawdowns Drawdowns are back to zero, after making our 22nd new high for 2026. The typical year has 18 new highs, so 2026 is well ahead of the game, with seven full months remaining. S&P 500 drawdowns (ZenInvestor) A look at the bull run since 2022 Is the market too high to put fresh money to work? No. Even in an expensive market like we have today, there are pockets of value available. Financials, Healthcare, and Consumer Staples are loaded with high quality companies that are trading at bargain prices. Small caps have rallied, but are still cheaper than their larger cousins. Bull run since 2022 (ZenInvestor) Major index performance last week Nasdaq stocks dominated last week, especially the Nasdaq 100, which is where many of the hyperscalers live. Microcaps have been moving up sharply, which underscores the broadening of the rally. Indices returns last week (ZenInvestor) Major asset class performance ...
J Studios/DigitalVision via Getty Images BitFuFu ( FUFU ) reported Q1 FY26 earnings yesterday (May 29), and the reported headline metric triggered a sell-off. FUFU went down ~8% on the earnings and closed yesterday's session at $1.86. The headline showed a $35 million GAAP net loss, increased from a $16.9 million loss in Q1 FY25. But the encouraging part is that the loss was mostly driven by a $35...
J Studios/DigitalVision via Getty Images BitFuFu ( FUFU ) reported Q1 FY26 earnings yesterday (May 29), and the reported headline metric triggered a sell-off. FUFU went down ~8% on the earnings and closed yesterday's session at $1.86. The headline showed a $35 million GAAP net loss, increased from a $16.9 million loss in Q1 FY25. But the encouraging part is that the loss was mostly driven by a $35.6 million non-cash fair value adjustment on BitFuFu's Bitcoin ( BTC-USD ) holdings due to Bitcoin's price swings in Q1. I have covered FUFU since 2024 and have reiterated a Buy on FUFU in all my previous coverages. I am downgrading FUFU to a Hold in this update. BitFuFu is one of the few digital asset mining companies that runs a flexible crypto mining business model, which helps the company hedge against volatility in times of Bitcoin price swings, just as we have witnessed with Bitcoin lately. The premise of my past Buy ratings has been based on the company's "dual-engine" architecture (combining cloud mining and self-mining economics), in addition to the fact that it was a fairly nascent miner founded in 2020, thus having room to grow hashrate and electricity capacity at scale. CoinWarz In the Q1 results, the dual-engine architecture is proving its worth as a fundamental hedge in the top line. When Bitcoin network difficulty ticks up (which reached new highs late last year and is up ~20% YoY) and hash price squeezes direct mining margins, BitFuFu unloads that operational risk onto cloud users while they earn from the more stable infrastructure fees from cloud mining. Q1 FY26 income snapshot (Q1 earnings press release) BitFuFu's total Q1 revenue came in at $72.7 million, a dip of 6.8% YoY. Despite the YoY revenue decline, the revenue composition is what is encouraging. Cloud mining revenue percentage of total revenue increased by 1030 basis points. In Q1, Cloud mining revenue made up 79.1% of total revenue compared to 68.8% a year ago. Q1 FY26 cost of revenue (Q1 earning...
Nico De Pasquale Photography/DigitalVision via Getty Images The Amplify CWP Growth & Income ETF ( QDVO ) has quickly become one of my favorite income vehicles in the market and the more I dig into the numbers the more conviction I have in its strategy. QDVO is one of the newer income-focused ETFs available after Amplify's success with the Amplify CWP Enhanced Dividend Income ETF ( DIVO ) and it's ...
Nico De Pasquale Photography/DigitalVision via Getty Images The Amplify CWP Growth & Income ETF ( QDVO ) has quickly become one of my favorite income vehicles in the market and the more I dig into the numbers the more conviction I have in its strategy. QDVO is one of the newer income-focused ETFs available after Amplify's success with the Amplify CWP Enhanced Dividend Income ETF ( DIVO ) and it's already pulled in $730 million in net assets since going public in August 2024. One of the most appealing parts is that QDVO continues to deliver a double digit distribution yield while keeping a portion of the portfolio uncapped so it can also produce modest appreciation when the markets move higher. That combination of recurring income and appreciation is exactly what I look for and it is why I have stayed bullish on QDVO in this market environment. This is not a fund that hands you a big yield and quietly bleeds your principal to pay for it. QDVO runs a tactical covered call overlay on a concentrated book of large-cap growth names. The aspect that is beneficial is that the managers are not bound to write calls on the entire portfolio at all times which means QDVO can lean into rallies instead of capping every dollar of upside the way a fully systematic covered call fund does. I believe that this approach will continue to replicate its previous metrics going forward. Seeking Alpha Following Up On My Previous Coverage Of QDVO At the beginning of February I had written an article on QDVO and since then its shares have appreciated by 6.77% while the S&P 500 has climbed by 8.68%. The total return from QDVO after the distribution is accounted for is 10.69% which is significantly higher than the market return. When I last wrote about QDVO my thesis was straightforward because QDVO stood out for its blend of income and appreciation. In that macroeconomic environment the risk free rate of return was expected to fall and I expected capital sitting in cash and short-term Treasuries...